From Nature to Bedside- Algae Based Bio Compound for Prevention and Treatment of Inflammation, Pain and IBD

Launched by FEDERICO II UNIVERSITY · Jan 18, 2024

Keywords

ClinConnect Summary

This clinical trial, called "From Nature to Bedside," is exploring a new way to treat Inflammatory Bowel Disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. The researchers are focusing on using natural compounds from algae to help reduce inflammation and pain in patients with these disorders. The goal is to find innovative treatments that can improve the overall quality of life for those who may not respond well to existing therapies.

To be eligible for the trial, participants need to be between 2 and 60 years old and must have a confirmed diagnosis of UC or CD. Patients will need to undergo standard medical procedures like endoscopies and biopsies as part of their regular care. Those without IBD can also participate if they are having similar procedures for other reasons. Throughout the study, participants will learn more about the effects of algae-based treatments in comparison to standard care, and all participants will provide informed consent before joining the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• SUBJECTS WITH THE DIAGNOSIS OF UC OR CD:
• • subjects undergoing endoscopy and biopsies collection per standard of care
• • patients ≥2 and \<60 years
• Additionally, for people with UC:
• • - clinical and endoscopic evaluation (Mayo score≥2)
• Additionally, for individuals with CD:
• • - clinical and endoscopic evaluation (Harvey-Bradshaw score ≥5 and overall simplified endoscopic score (SES-CD) \>2)
• SUBJECTS NOT AFFECTED BY UC OR CD:
• • subjects undergoing endoscopy and biopsies collection (≥2 and \<60 years) according to the normal clinical practice (as patients undergoing cancer surveillance, irritable bowel syndrome (IBS), diarrhea) subjects not affected by UC or CD according to the previously reported clinical and endoscopic evaluation criteria All patients will sign the informed consent.
• Exclusion Criteria:
• SUBJECTS WITH THE DIAGNOSIS OF UC OR CD:
• • - subjects with UC or CD who do not have the previously described clinical and endoscopic evaluation criteria
• SUBJECTS NOT AFFECTED BY UC OR CD (CONTROL GROUP):
• • -subjects undergoing anti-inflammatory and/or immunosuppressive treatments for other diseases not related to UC or CD